Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Intrinsic Value
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. [ Read More ]
The intrinsic value of one
ALNY
stock under the Base Case scenario is
182.78
USD.
Compared to the current market price of 144.41 USD,
Alnylam Pharmaceuticals Inc
is
Undervalued by 21%.
Alnylam Pharmaceuticals Inc's market capitalization is 18.2B USD.
ALNY stock price is 144.41 USD.
ALNY stock price (144.41 USD) is 21% less than its Intrinsic Value (182.78 USD).
ALNY stock price (144.41 USD) is 56% less than its Relative Value (325.78 USD). Open Relative Valuation
ALNY has upside potential of 57% compared to the average analyst price target.
Open Wall St Estimates
ALNY's long-term liabilties (4B USD) exceed its long-term assets (4B USD).
ALNY's Revenue is forecast to grow at a rate of 21% per year over the next 3 years.
ALNY's Revenue has grown by an exceptional 76% over the past 12 months.
ALNY's ROE (Return on Equity) has significantly increased in the last 3 years from -77% to 232%.
ALNY's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -67% to -22%, and is approaching profitability.
ALNY has negative Operating Income for the last twelve months.
ALNY has negative Net Income for the last twelve months.
ALNY's ROE (Return on Equity) for the past 12 months is very high and is equal to 232%.
ALNY's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -22%.
ALNY has negative Net Debt. This means that the company has more cash and short-term investments (2B USD) than debt (1B USD).
ALNY has positive Gross Profit for the last twelve months.
ALNY's Revenue has been growing by an exceptional 55% per year for the last 3 years.
ALNY's short-term assets (3B USD) exceed its short-term liabilties (968m USD).
ALNY has positive Free Cash Flow for the last twelve months.
ALNY's Altman Z-Score is very low and is equal to 1.11.
ALNY has negative three-year average ROE (Return on Equity): -117%. The company is not efficient at transforming stockholders' equity into net income.
ALNY has negative three-year average ROIC (Return on Invested Capital): -56%. The company is not efficient at using invested capital to generate operating income.
ALNY's D/E (Debt to Equity) is very low and is equal to -4.63.
ALNY doesn't generate enough operating income (-282m USD) to safely cover interest payments on its debt (32m USD).
Valuation Backtest
Alnylam Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
ALNY
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Alnylam Pharmaceuticals Inc
Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc
| Current Assets | 3B |
| Cash & Short-Term Investments | 2.4B |
| Receivables | 327.8m |
| Other Current Assets | 215.5m |
| Non-Current Assets | 847.2m |
| PP&E | 725.8m |
| Other Non-Current Assets | 121.4m |
| Current Liabilities | 967.8m |
| Accounts Payable | 55.5m |
| Accrued Liabilities | 754.5m |
| Other Current Liabilities | 157.7m |
| Non-Current Liabilities | 3.1B |
| Long-Term Debt | 1B |
| Other Non-Current Liabilities | 2.1B |
Earnings Waterfall
Alnylam Pharmaceuticals Inc
|
Revenue
|
1.8B
USD
|
|
Cost of Revenue
|
-310.4m
USD
|
|
Gross Profit
|
1.5B
USD
|
|
Operating Expenses
|
-1.8B
USD
|
|
Operating Income
|
-282.2m
USD
|
|
Other Expenses
|
-158.1m
USD
|
|
Net Income
|
-440.2m
USD
|
Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc
What is Free Cash Flow?
ALNY Profitability Score
Profitability Due Diligence
Alnylam Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Alnylam Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
ALNY Solvency Score
Solvency Due Diligence
Alnylam Pharmaceuticals Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Alnylam Pharmaceuticals Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ALNY
is 227.14 USD
with a low forecast of 137.36 USD and a high forecast of 414.75 USD.
Ownership
ALNY Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ALNY Price
Alnylam Pharmaceuticals Inc
| Average Annual Return | 29.98% |
| Standard Deviation of Annual Returns | 12.94% |
| Max Drawdown | -40% |
| Market Capitalization | 18.2B USD |
| Shares Outstanding | 125 613 000 |
| Percentage of Shares Shorted | 2.55% |
ALNY News
Last Important Events
Alnylam Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Alnylam Pharmaceuticals Inc
Company Profile
Alnylam Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1,665 full-time employees. The company went IPO on 2004-05-28. The company is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALNY
stock under the Base Case scenario is
182.78
USD.
Compared to the current market price of 144.41 USD,
Alnylam Pharmaceuticals Inc
is
Undervalued by 21%.
You don't have any saved screeners yet
